Search

Your search keyword '"Groshkova, Teodora"' showing total 149 results
Start Over Author "Groshkova, Teodora" Publication Year Range Last 50 years
149 results on '"Groshkova, Teodora"'

7. Commentary on Pardo et al.: Whatever the past situation, drug precursor chemicals may in future represent an important source for synthetic drug production in Afghanistan and surrounding countries.

Author

Soderholm, Alexander, Mansfield, David, Groshkova, Teodora, Sedefov, Roumen, and Griffiths, Paul

Subjects
PRODRUGS, METHAMPHETAMINE, PHARMACEUTICAL industry, SYNTHETIC drugs, DRUGS
Abstract

The article comments on the paper by B. Pardo and colleagues about the production of methamphetamine in Afghanistan. Topics discussed include the role of ephedra in the expansion of methamphetamine production in the country, the uncertainty of the Taliban's ban on drug production, and the possible increase in the manufacture of methamphetamine or other synthetic substances using synthetic precursors.

Published
2024
Full Text
View/download PDF

10. The iCannTookit: a consensus‐based, flexible framework for measuring contemporary cannabis use

Author

Lorenzetti, Valentina, primary, Hindocha, Chandni, additional, Petrilli, Kat, additional, Griffiths, Paul, additional, Brown, Jamie, additional, Castillo‐Carniglia, Álvaro, additional, Caulkins, Jonathan P., additional, Englund, Amir, additional, El Sohly, Mahmoud A., additional, Gage, Suzanne H., additional, Groshkova, Teodora, additional, Gual, Antoni, additional, Hammond, David, additional, Lawn, Will, additional, López‐Pelayo, Hugo, additional, Manthey, Jakob, additional, Mokrysz, Claire, additional, Liccardo Pacula, Rosalie, additional, van Laar, Margriet, additional, Vandrey, Ryan, additional, Wadsworth, Elle, additional, Winstock, Adam, additional, Hall, Wayne, additional, Curran, H. Valerie, additional, and Freeman, Tom P., additional

Published
2022
Full Text
View/download PDF

11. The iCannToolkit: a tool to embrace measurement of medicinal and non‐medicinal cannabis use across licit, illicit and cross‐cultural settings

Author

Lorenzetti, Valentina, primary, Hindocha, Chandni, additional, Petrilli, Kat, additional, Griffiths, Paul, additional, Brown, Jamie, additional, Castillo‐Carniglia, Álvaro, additional, Caulkins, Jonathan P., additional, Englund, Amir, additional, ElSohly, Mahmoud A., additional, Gage, Suzanne H., additional, Groshkova, Teodora, additional, Gual, Antoni, additional, Hammond, David, additional, Lawn, Will, additional, López‐Pelayo, Hugo, additional, Manthey, Jakob, additional, Mokrysz, Claire, additional, Liccardo Pacula, Rosalie, additional, Laar, Margriet, additional, Vandrey, Ryan, additional, Wadsworth, Elle, additional, Winstock, Adam, additional, Hall, Wayne, additional, Curran, H. Valerie, additional, and Freeman, Tom P., additional

Published
2022
Full Text
View/download PDF

12. The International Cannabis Toolkit (iCannToolkit): a multidisciplinary expert consensus on minimum standards for measuring cannabis use

Author

Lorenzetti, Valentina, primary, Hindocha, Chandni, additional, Petrilli, Kat, additional, Griffiths, Paul, additional, Brown, Jamie, additional, Castillo‐Carniglia, Álvaro, additional, Caulkins, Jonathan P., additional, Englund, Amir, additional, ElSohly, Mahmoud A., additional, Gage, Suzanne H., additional, Groshkova, Teodora, additional, Gual, Antoni, additional, Hammond, David, additional, Lawn, Will, additional, López‐Pelayo, Hugo, additional, Manthey, Jakob, additional, Mokrysz, Claire, additional, Pacula, Rosalie Liccardo, additional, Laar, Margriet, additional, Vandrey, Ryan, additional, Wadsworth, Elle, additional, Winstock, Adam, additional, Hall, Wayne, additional, Curran, H. Valerie, additional, and Freeman, Tom P., additional

Published
2021
Full Text
View/download PDF

18. The International Cannabis Toolkit (iCannToolkit): a multidisciplinary expert consensus on minimum standards for measuring cannabis use.

Author

Lorenzetti, Valentina, Hindocha, Chandni, Petrilli, Kat, Griffiths, Paul, Brown, Jamie, Castillo‐Carniglia, Álvaro, Caulkins, Jonathan P., Englund, Amir, ElSohly, Mahmoud A., Gage, Suzanne H., Groshkova, Teodora, Gual, Antoni, Hammond, David, Lawn, Will, López‐Pelayo, Hugo, Manthey, Jakob, Mokrysz, Claire, Pacula, Rosalie Liccardo, van Laar, Margriet, and Vandrey, Ryan

Subjects
CANNABIS (Genus), CONSENSUS (Social sciences), DRUG utilization statistics, SELF-evaluation, DRUG utilization
Abstract

Background: The lack of an agreed international minimum approach to measuring cannabis use hinders the integration of multidisciplinary evidence on the psychosocial, neurocognitive, clinical and public health consequences of cannabis use. Methods: A group of 25 international expert cannabis researchers convened to discuss a multidisciplinary framework for minimum standards to measure cannabis use globally in diverse settings. Results: The expert‐based consensus agreed upon a three‐layered hierarchical framework. Each layer—universal measures, detailed self‐report and biological measures—reflected different research priorities and minimum standards, costs and ease of implementation. Additional work is needed to develop valid and precise assessments. Conclusions: Consistent use of the proposed framework across research, public health, clinical practice and medical settings would facilitate harmonisation of international evidence on cannabis consumption, related harms and approaches to their mitigation. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

27. Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention

Author

Wiessing, Lucas Ferri, Marica Grady, Bart Kantzanou, Maria and Sperle, Ida Cullen, Katelyn J. Hatzakis, Angelos Prins, Maria Vickerman, Peter Lazarus, Jeffrey V. Hope, Vivian D. and Mathei, Catharina Busch, Martin Bollaerts, Kaat and Bogdanova, Violeta Nesheva, Elmira Fotsiou, Nasia Kostrikis, Leontios Mravcik, Viktor Rehak, Vratislav Castkova, Jitka and Hobstova, Jirlina Nechanska, Blanka Fouchard, Jan and Abel-Ollo, Katri Tefanova, Valentina Tallo, Tatjana and Brummer-Korvenkontio, Henrikki Brisacier, Anne-Claire Michot, Isabelle Jauffret-Roustide, Marie Zimmermann, Ruth Fotiou, Anastasios Gazdag, Gabor Tarjan, Anna Galvin, Brian and Garavan, Carrie Thornton, Lelia Cruciani, Mario Basso, Monica Karnite, Anda Caplinskiene, Irma Lopes, Sofia and Origer, Alain Melillo, Jackie Camilleri, Moses Demanuele, Carlo Olivari Croes, Esther Op de Coul, Eline Rosinska, Magdalena Struzik, Marta Martins, Mario Duran, Domingos and Vilar, Graca Resende, Emilia Martins, Helena Cortes Abagiu, Adrian Octavian Ruta, Simona Arama, Victoria Kopilovic, Boris Kustec, Tanja Klavs, Irena Aleixandre, Noelia Llorens and Folch, Cinta Bravo, Maria Jose Gomez, Rosario Sendino and Berglund, Torsten Strandberg, Joakim Hope, Vivian Hotho, Daphne Van Houdt, Sabine Low, Andrea Mcdonald, Bethan and Platt, Lucy Isabelle Giraudon, Eleni Kalamara Groshkova, Teodora and Palladino, Claudia Hutchinson, Sharon Ncube, Fortune and Eramova, Irina Goldberg, David Vicente, Julian Griffiths, Paul EMCDDA DRID Grp

Abstract

Background: People who inject drugs (PWID) are a key population affected by hepatitis C virus (HCV). Treatment options are improving and may enhance prevention; however access for PWID may be poor. The availability in the literature of information on seven main topic areas (incidence, chronicity, genotypes, HIV co-infection, diagnosis and treatment uptake, and burden of disease) to guide HCV treatment and prevention scale-up for PWID in the 27 countries of the European Union is systematically reviewed. Methods and Findings: We searched MEDLINE, EMBASE and Cochrane Library for publications between 1 January 2000 and 31 December 2012, with a search strategy of general keywords regarding viral hepatitis, substance abuse and geographic scope, as well as topic-specific keywords. Additional articles were found through structured email consultations with a large European expert network. Data availability was highly variable and important limitations existed in comparability and representativeness. Nine of 27 countries had data on HCV incidence among PWID, which was often high (2.7-66/100 person-years, median 13, Interquartile range (IQR) 8.7-28). Most common HCV genotypes were G1 and G3; however, G4 may be increasing, while the proportion of traditionally ‘difficult to treat’ genotypes (G1+G4) showed large variation (median 53,IQR 43-62). Twelve countries reported on HCV chronicity (median 72, IQR 64-81) and 22 on HIV prevalence in HCV-infected PWID (median 3.9%, IQR 0.2-28). Undiagnosed infection, assessed in five countries, was high (median 49%, IQR 38-64), while of those diagnosed, the proportion entering treatment was low (median 9.5%, IQR 3.5-15). Burden of disease, where assessed, was high and will rise in the next decade. Conclusion: Key data on HCV epidemiology, care and disease burden among PWID in Europe are sparse but suggest many undiagnosed infections and poor treatment uptake. Stronger efforts are needed to improve data availability to guide an increase in HCV treatment among PWID.

Published
2014

28. Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review

Author

Mravcik, Viktor, Strada,Lisa, Å tolfa,Josef, Bencko,Bladimir, Groshkova,Teodora, Reimer,Jens, and Schulte,Bernd

Subjects
Patient Preference and Adherence
Abstract

Viktor Mravčík,1,2 Lisa Strada,3 Josef Štolfa,4,5 Vladimir Bencko,6 Teodora Groshkova,7 Jens Reimer,3 Bernd Schulte3 1National Monitoring Centre for Drugs and Drug Addiction, 2Department of Addictology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic; 3Centre for Interdisciplinary Addiction Research, University of Hamburg, Hamburg, Germany; 4Department of General Practice, Institute for Postgraduate Medical Education in Prague, 5Department of General Practice, Second Faculty of Medicine, 6Institute of Hygiene and Epidemiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic; 7European Monitoring Centre for Drugs and Drug Addiction, Lisbon, Portugal Introduction and methods: Hepatitis C virus (HCV) infections are highly prevalent amongst people who inject drugs (PWID). Despite well documented evidence of its effectiveness, suggested cost-effectiveness, and potential to reduce HCV prevalence rates, the uptake of antiviral HCV treatment by PWID is low. This nonsystematic literature review describes factors associated with the uptake, adherence, and efficacy of HCV treatment among PWID and discusses strategies to increase their uptake of treatment. Results: Low HCV treatment uptake among PWID is associated with a number of patient-related and provider-related barriers. Beliefs and fears about low efficacy and adverse effects on the patient’s part are common. A substantial number of factors are associated with the chaotic lifestyle and altered social functioning of PWID, which are often associated with decompensation or relapsing into drug addiction. This may lead to perceived low adherence with treatment and low efficacy on the provider’s part too, where lack of support, inadequate management of addiction, and other drug-related problems and poor treatment of side effects have been described. Practical issues such as the accessibility of treatment and finances also play a role. Strategies to improve the HCV treatment rate among PWID involve pretreatment management and assessment, a multidisciplinary approach, management of side effects, and enhanced education and counseling. Conclusion: Specific factors are associated with poorer treatment outcomes in PWID on the side of both the patient and the treatment system. However, given that PWID can achieve treatment adherence and sustained virologic response rates comparable with those in nondrug users, drug use per se should not be considered a criterion for exclusion from treatment. Further development of measures leading to higher uptake of treatment and adherence in PWID and appropriate adaptation of HCV treatment guidelines represent important tools in this regard. Keywords: hepatitis C virus, people who inject drugs, treatment uptake, adherence, efficacy

Published
2013

29. Drug use, health and social outcomes of hard-to-treat heroin addicts receiving supervised injectable opiate treatment: secondary outcomes from the Randomized Injectable Opioid Treatment Trial (RIOTT)

Author

Metrebian, Nicola, primary, Groshkova, Teodora, additional, Hellier, Jennifer, additional, Charles, Vikki, additional, Martin, Anthea, additional, Forzisi, Luciana, additional, Lintzeris, Nicholas, additional, Zador, Deborah, additional, Williams, Hugh, additional, Carnwath, Tom, additional, Mayet, Soraya, additional, and Strang, John, additional

Published
2014
Full Text
View/download PDF

30. Authors' reply

Author

Byford, Sarah, primary, Barrett, Barbara, additional, Metrebian, Nicola, additional, Groshkova, Teodora, additional, Cary, Maria, additional, Charles, Vikki, additional, Lintzeris, Nicholas, additional, and Strang, John, additional

Published
2014
Full Text
View/download PDF

31. Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review

Author

Mravčík,Viktor, Strada,Lisa, Štolfa,Josef, Bencko,Vladimir, Groshkova,Teodora, Reimer,Jens, Schulte,Bernd, Mravčík,Viktor, Strada,Lisa, Štolfa,Josef, Bencko,Vladimir, Groshkova,Teodora, Reimer,Jens, and Schulte,Bernd

Abstract

Viktor Mravčík,1,2 Lisa Strada,3 Josef Štolfa,4,5 Vladimir Bencko,6 Teodora Groshkova,7 Jens Reimer,3 Bernd Schulte3 1National Monitoring Centre for Drugs and Drug Addiction, 2Department of Addictology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic; 3Centre for Interdisciplinary Addiction Research, University of Hamburg, Hamburg, Germany; 4Department of General Practice, Institute for Postgraduate Medical Education in Prague, 5Department of General Practice, Second Faculty of Medicine, 6Institute of Hygiene and Epidemiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic; 7European Monitoring Centre for Drugs and Drug Addiction, Lisbon, Portugal Introduction and methods: Hepatitis C virus (HCV) infections are highly prevalent amongst people who inject drugs (PWID). Despite well documented evidence of its effectiveness, suggested cost-effectiveness, and potential to reduce HCV prevalence rates, the uptake of antiviral HCV treatment by PWID is low. This nonsystematic literature review describes factors associated with the uptake, adherence, and efficacy of HCV treatment among PWID and discusses strategies to increase their uptake of treatment. Results: Low HCV treatment uptake among PWID is associated with a number of patient-related and provider-related barriers. Beliefs and fears about low efficacy and adverse effects on the patient’s part are common. A substantial number of factors are associated with the chaotic lifestyle and altered social functioning of PWID, which are often associated with decompensation or relapsing into drug addiction. This may lead to perceived low adherence with treatment and low efficacy on the provider’s part too, where lack of support, inadequate management of addiction, and other drug-related problems and poor treatment of side effects have been described. Practical issues such as the accessibility of treatment and finances also

Published
2013

47. Identifying and Recruiting Recovery Champions: Exploratory Action Research in Barnsley, South Yorkshire.

Author

Best, David, Loudon, Lorraine, Powell, Diana, Groshkova, Teodora, and White, William

Subjects
PREVENTION of alcoholism, SUBSTANCE abuse treatment, SUBSTANCE abuse, ASIANS, BLACK people, CONVALESCENCE, INTERVIEWING, SUPPORT groups, WHITE people, ADULT education workshops, TREATMENT programs, DATA analysis software
Abstract

The UK Drug Strategy has embraced the philosophy of recovery as an “individual, person-centered journey” (Her Majesty's [HM] Government, 2010, p. 19) and is supported by a local network of recovery champions. The purpose of this article is to examine proactive attempts at establishing such networks based on training and working with a mixture of people in recovery and professionals, supported by a local recovery leader. What is presented in this article is a case study of an initiative attempting to access and link recovery champions. The early stages of the initiative were planned in advance, but the later stages were evolutionary and were based on the decisions of the emerging recovery champions group. The initiative started with a series of workshops to raise awareness about recovery, and from this, to recruit an initial group of candidate champions. Small groups were successfully recruited to participate in subsequent champions workshops, and they have since translated that commitment to a range of actions and directions, which have attempted to generate a visible recovery community and to challenge stereotypes and stigma perceptions. The final section of the article will review the utility of the label of “recovery champion” and will examine the role of such networks in enabling and supporting the emergence of a local culture of recovery. [ABSTRACT FROM PUBLISHER]

Published
2013
Full Text
View/download PDF

48. Looking to the future—more concern than optimism that cryptomarkets will reduce drug‐related harms.

Author

Mounteney, Jane, Cunningham, Andrew, Groshkova, Teodora, Sedefov, Roumen, and Griffiths, Paul

Subjects
DRUGS of abuse, ONLINE marketplaces, DRUG traffic, PRICES, HARM reduction
Abstract

The term ‘quality’ is ambiguous when referring to illicit drug sales, and cautious use is required in the context of a discussion of harms. Monitoring of the future trajectories for darknet markets and their implications will be important going forward. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

50. EMCDDA to chair JHA agencies' network in 2017.

Author

Palczak, Klaudia, Groshkova, Teodora, and De Neve, Renate

Subjects
GOVERNMENT agencies, PREVENTION of drug addiction
Abstract

The article reports that the network of nine European Union (EU) Justice and Home Affairs agencies (JHA network) will be leading by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) from January to December 31, 2017.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results